What is the current size of the monkeypox testing market?

In 2027 the market for monkeypox testing is worth approximately USD 2.34 million.

What is the forecasted size of the monkeypox testing industry?

Monkeypox Testing Market size was over USD 2.26 million in 2026 and is likely to grow at a 4.09% CAGR between 2027 and 2036, exceeding USD 3.37 million by 2036.

How are government surveillance initiatives influencing demand in the monkeypox testing market?

Government-led surveillance programs increase procurement of testing assays, reagents, and laboratory services by emphasizing rapid case confirmation, higher testing throughput, and compatibility with structured public health monitoring systems.

Why is decentralized testing infrastructure becoming strategically important in the monkeypox testing market?

Expanding decentralized testing improves diagnostic access and shortens confirmation times, encouraging health systems to invest in portable, simplified testing platforms that strengthen outbreak preparedness and operational responsiveness.

Why does PCR dominate monkeypox diagnostic testing?

PCR held the largest share in 2026 due to its high diagnostic accuracy, established laboratory integration, and critical role in confirmatory testing for clinical and public health decision-making.

What is driving growth in lateral flow assay (LFA) testing?

LFA is the fastest-growing segment as demand rises for rapid, decentralized testing solutions that enable quicker screening and easier deployment outside traditional laboratory settings.

Why is North America the leading region in the monkeypox testing market?

North America accounted for 42.45% of the market in 2026, supported by advanced diagnostic infrastructure, strong laboratory capacity, and efficient integration of disease surveillance into healthcare systems.

What is driving growth in the monkeypox testing market across Asia Pacific?

Asia Pacific is projected to grow at a 5.13% CAGR, driven by expanding diagnostic access, stronger public health monitoring, and greater investment in outbreak preparedness and molecular testing capabilities.

Who are the leading players in the monkeypox testing landscape?

Key companies in the monkeypox testing market include Thermo Fisher Scientific Inc. (United States), QIAGEN N.V. (Netherlands), Quest Diagnostics Incorporated (United States), Laboratory Corporation of America Holdings (United States), Becton, Dickinson and Company (United States), Mayo Clinic Laboratories (United States), Aegis Sciences Corporation (United States), Chembio Diagnostics, Inc. (United States), Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd (Switzerland).